Search Results - "Veltri, E.P."

Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial[S] by Jakulj, L., Vissers, M.N., Groen, A.K., Hutten, B.A., Lutjohann, D., Veltri, E.P., Kastelein, J.J.P.

“…Subjects with increased cholesterol absorption might benefit more from statin therapy combined with a cholesterol absorption inhibitor. We assessed whether…”
Get full text

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia by Knopp, R.H., Gitter, H., Truitt, T., Bays, H., Manion, C.V., Lipka, L.J., LeBeaut, A.P., Suresh, R., Yang, B., Veltri, E.P.

“…Aims This randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of ezetimibe 10mg/day in patients with primary…”
Get full text

Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia by Ballantyne, C M, Lipka, L J, Sager, P T, Strony, J, Alizadeh, J, Suresh, R, Veltri, E P

“…Long-term safety and tolerability of ezetimibe plus atorvastatin (EZE + ATV) coadministration therapy were compared to those of ATV monotherapy in patients…”
Get more information

901–41 Preliminary Mortality Results from the Survival with Oral D-Sotalol (SWORD) Trial by Waldo, A.L., Camm, A.J., de Ruyter, H., Friedman, P.L., MacNeil, D.J., Pitt, B., Pratt, C.M., Schwartz, P.J., Veltri, E.P.

“…The SWORD trial was designed to enroll 6400 patients to test the hypothesis that d-Sotalol would reduce total mortality in high risk survivors of a myocardial…”
Get full text

Effect of ezetimibe on serum concentrations of lipid-soluble vitamins by Knopp, R.H., Bays, H., Manion, C.V., Lipka, L.J., Melani, L., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text

Ezetimibe does not decrease the response to cosyntropin stimulation by Bays, H., Knopp, R.H., Mardon, C.V., Lipka, L.J., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text

Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial by Knopp, R.H., Gitter, H., Truitt, T., Lipka, L.J., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text

Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CIII and LDL subfractions by Kosoglou, T., Fruchart, J.-C., Guillaume, M., Pember, L.J.C., Sun, S., Picard, G., Affrime, M.B., Veltri, E.P.

Get full text

Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications by Kosoglou, T., Meyer, I., Musiol, B., Anderson, L., Reyderman, L., Statkevich, P., Cutler, D.L., Veltri, E.P., Affrime, M.B.

Get full text

Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe by Kosoglou, T., Guillaume, M., Sun, S., Pember, L.J.C., Reyderman, L., Statkevich, P., Cutler, D.L., Veltri, E.P., Affrime, M.B.

Get full text